| Sunday Evening | Keynote Lecture |
Chairman's Welcome and Remarks
Sir Philip Cohen (Department of Biochemistry, University of Dundee, Scotland)
The Development of Specific Protein Kinase Inhibitors as Drugs
| Monday Morning | New Technological Developments for the Study of Drug Metabolism |
Discussion Leader: Colin Garner
Dr Colin Garner (Centre for Biomedical Accelerator Mass Spectrometry, York, England)
Ultrasensitive Analysis of Drugs and Metabolites using Accelerator Mass Spectrometry
Dr Tom Rushmore (Merck, West Point)
Using DNA micro-arrays to assess the response of many genes to one drug candidate
Dr George Kabalka (Departments of Chemistry and Radiology, University of Tennessee)
Positron Tomography as a Tool for the Development and Evaluation of New Drugs
| Monday Evening | Hepatocytes; Drug Metabolism and Drug Induction |
Discussion leader: Cosette Serabjit-Singh (Glaxo Wellcome Inc, RTP, North Carolina)
Dr Ronald Laethem (Glaxo Wellcome Inc, Research Triangle Park, North Carolina)
Drug Discovery, Predicting the Disposition of New Medicines
Dr Stephen Strom (Pathology, University of Pittsburg)
Modelling Human Hepatic Function in vivo
| Tuesday Morning | Clinically Relevant Pharmacokinetic Drug Interactions |
Discussion Leader: Chris Kemper (Phoenix International, Bedmister, NJ)
Dr Irving Wainer (Pharmacology, Georgetown University, Washington)
Discordance between Genotype and Phenotype: Disease Induced Changes in Drug Metabolism
Dr Jacques Turgeon (Phoenix International, Bedminster, NJ)
Cytochrome P450 Interactions and Drug Actions on the Cardiovascular Systems: Could We Better Handle the Beast?
Dr Brian Campbell Foster (Therapeutics Products Programme, Ottawa, Ontario)
Clinically Relevant Drug Interactions in Persons with HIV/AIDS: From the Frypan into the Fire
| Tuesday Evening | Defining the Role of Drug Transporters in Drug Disposition and Drug Interactions: From Animals to Humans |
Discussion Leader: Kim Brouwer (Pharmacy, University of North Carolina, NC)
Dr Irwin Arias (Dept of Physiology, Tufts University)
Bile Canalicular ABC Transporters: Function, Targeting and Regulation
Dr Hiroshi Suzuki (Dept of Pharmaceutics, University of Tokyo)
Role of MRP Transporters in Hepatic, Intestinal and CNS Drug Disposition: Applications to New Drug Development
| Wednesday Morning | Active Site Modelling of Enzymes of Drug Metabolism |
Discussion Leader: Steve Wrighton (Eli Lilly, Indianapolis)
Dr Sean Ekins (Eli Lilly, Indianapolis)
In Silico Approaches for Understanding Substrate and Inhibitor Interactions with CYP450
Dr Peter Swaan (College of Pharmacy, Columbus, OH)
Modelling of Membrane Transporters: Towards Predicting Substrate Affinity In Silico
Dr Marcel de Groot (Pfizer, Kent, UK)
Predicting CYP2D6 Mediated Drug Metabolism
| Wednesday Evening | Cytochrome P450 Mechanisms |
Discussion Leader: Alan Rettie (Medicinal Chemistry, University of Washington, Seattle)
Dr Alfin Vaz (Pfizer Central Research, Groton, CT)
Implications of Mutiple Cytochrome P450 Oxidants in Drug Metabolism
Dr Kent Kunze (Medicinal Chemistry, University of Washington, Seattle)
Pre- and Post-Abstraction Riddles in the Metabolism of 8-Alkyl Xanthines by CYP1A2
| Thursday Morning | Cytochrome P450 Active Site |
Discussion Leader: Henry Strobel (Biochemistry and Molecular Biology, University of Texas Medical School, Houston)
Dr Almira Correia (Cellular and Molecular Pharmacology, UCSF, San Francisco)
Cytochrome P450 Active Site Modifications: Benign and Lethal Consequences
Dr Peter Hodek (Biochemistry, Charles University, Prague)
Insight into the CYP Active Site by Means of Modification Techniques
Dr Wayne Backes (Pharmacology, LSU Medical Center)
Organisation of Reductase with Multiple P450 Enzymes
| Thursday Evening | Selected Presentations from the Poster Session |
Discussion Leader: Brian Burchell (Molecular and Cellular Pathology, University of Dundee)
4 or 5 Presentations to be announced at a later date
7.30 - 8.30 AM Breakfast
9 AM Departure for Logan Airport
| 